ArticleEJHaem2026
Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies.Blood cancer journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Introduction: Multiple myeloma treatment has rapidly evolved, but little is known about the uptake of guideline-recommended triplet or quadruplet therapy in clinical practice. Methods: This retrospective cohort study included adult patients newly diagnosed with multiple myeloma between January 1, 2017, and December 31, 2023, in one health system in Ohio and Florida. Receipt of triplet or quadruplet therapy within 1 year of diagnosis was quantified to investigate its association with sociodemographic and clinical factors, using a multivariable logistic regression model. We also captured patients' overall survival (OS) through September 30, 2025, using the Cleveland Clinic electronic health record, including linked state and federal death records. Results: We identified 1230 patients, with mean (SD) age at diagnosis of 67.2 (11.1), 54.1% male, 74.1% White, and 22.8% Black. Within 1 year of diagnosis, 707 (57.5%) patients received either triplet or quadruplet therapy. Utilization increased from 57.1% to 65.9% between 2017 and 2023. In a multivariable logistic regression model, patients who were older, resided in more disadvantaged neighborhoods, or were treated at a Florida regional hospital (vs. Taussig Cancer Center) had lower odds of triplet or quadruplet regimen within 1 year of diagnosis, while those diagnosed in 2023, treated at an Ohio regional hospital, having an eGFR < 60, or a Charlson Comorbidity Score of ≥ 3 had higher odds. The probability of 5-year OS in the cohort was 62.1% (95% CI, 59.0%-65.4%). Conclusion: Our real-world data demonstrate the association of sociodemographic and clinical factors with therapy selection and show improved 5-year OS in clinical practice compared to historical trends. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.